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Background: Several prognostic indexes (PI) have been developed in the brain metastases (BM) setting to help
physicians tailor treatment options and stratify patients enrolled in clinical studies. The aim of our study was to
compare the clinical relevance of the major PI for breast cancer BM.
Methods: Clinical and biological data of 250 breast cancer patients diagnosed with BM at two institutions between
1995 and 2010 were retrospectively reviewed. The prognostic value and accuracy of recursive partitioning analysis
(RPA), graded prognostic assessment (GPA), basic score for BM (BS-BM), breast RPA, breast GPA, Le Scodan’s Score
and a clinico-biological score developed in a phase I study (P1PS) were assessed using Cox regression models. PI
comparison was performed using Harrell’s concordance index.
Results: After a median follow-up of 4.5 years, median overall survival (OS) from BM diagnosis was 8.9 months (CI
95%, 6.9–10.3 months). All PI were significantly associated with OS. Harrell’s concordance indexes C favored BS-BM
and RPA. In multivariate analysis, the RPA, Le Scodan’s score and GPA were found to be the best independent
predictors of OS. In multivariate analysis restricted to the 159 patients with known LDH and proteinemia, RPA 2 and
3, Le Scodan’s Score 3 and P1PS 2/3 were associated with worse survival. RPA was the most accurate score to
identify patients with long (superior to 12 months) and short (inferior to 3 months) life expectancy.
Conclusions: RPA seems to be the most useful score and performs better than new PI for breast cancer BM.
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The Recursive Partitioning Analysis RPA [1] was the first
prognostic score developed in the brain metastases (BM)
setting. This classification was created in 1997 by the Ra-
diation Therapy Oncology Group after analysis of the rela-
tive contributions of pretreatment variables to survival of
patients with BM. Since this date, several scores and prog-
nostic indexes (PI), such as the Graded Prognosis Assess-
ment (GPA) [2], the Basic Score for BM (BS-BM) [3], the
Phase 1 Prognostic Score (P1PS) [4], the Rotterdam score
[5], the Score Index for Radiosurgery (SIR) [6] and the
Rades’s score [7] have been developed both to help physi-
cians tailor treatment options depending on patient* Correspondence: Antoine.Braccini@montpellier.unicancer.fr
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reproduction in any medium, provided the orprognosis, and to stratify patients enrolled in clinical stud-
ies. However, it has been demonstrated that the prognostic
value of these scoring systems differs according to the pri-
mary tumor site [8], which raises the question of the use-
fulness of a breast-specific score.
Breast cancer is the second cause of BM, after lung can-
cer. Breast cancer is a heterogeneous disease with meta-
static pattern and survival varying with the expression of
biological markers such as the hormonal receptor (HR)
status and human epidermal growth factor receptor-2
(HER2) overexpression. While the incidence of BM from
breast cancer has increased over the past decade, espe-
cially for the subgroup of HER2-overexpressing tumors,
several studies have shown that biological subtypes influ-
ence survival, even after BM diagnosis. In a series of 223
breast cancer patients irradiated for BM, Dawood et al.
showed that HER2 positive status was an independentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Prognostic indexes parameters
A: Clinical parameters used for 5 prognostic indexes (RPA, GPA, BS-
BM, Breast RPA, and Breast GPA).
RPA
Class 1 Age <65 y, KPS≥ 70, controlled primary tumor, no
extracranial metastases
Class 2 All patients not in Class I or III
Class 3 KPS < 70
GPA
0 0,5 1
Age > 60 50-59 <50
KPS <70 70-80 90-100
Number of BM > 3 2-3 1




Control of primary tumor No Yes
Extracranial metastases Yes No
Breast RPA
Class 1 1–2 brain metastases and extracranial disease absent
or controlled and KPS 100
Class 2 All patients not in Class I or III
Class 3 Multiple brain metastases and KPS≤ 60
Breast GPA
0 0,5 1 1.5 2
Age ≥ 60 <60
KPS ≤ 50 60 70-80 90-100
Genetic subtype Basal Luminal A HER2 Luminal B




Sites of metastases 0-2 >2
Serum LDH <ULN >ULN
Albumin, g/L ≥35 <35
Le Scodan Score
Class I HER2+ tumors treated with trastuzumab
Class II All patients not in Class I or III
Class III Tumors not treated with trastuzumab and:
lymphopenia at BM diagnosis or KPS < 70
and≥ 50 years old at BM diagnosis or KPS ≥ 70
and triple negative tumors
RPA, Recursive Partitioning Analysis, GPA, Graded Partitioning Analysis, BS-BM,
Basic Score for Brain Metastases, BM, Brain Metastases, P1PS, phase 1
prognostic score, KPS, Karnofsky Performance Status, BM, Brain Metastases,
LDH, Lactate Dehydrogenase, ULN, Upper Limit of Normal.
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negative population seems to be associated with worse
prognosis [10,11]. These results have prompted the devel-
opment of specific prognostic scores for BM from breast
cancer taking into account either tumor phenotypic char-
acteristics [12,13] or not [14]. Given the number of scor-
ing systems that have been devised for clinical use, the
aim of our study was to compare the clinical relevance of
the major existing prognostic scores in a cohort of breast
cancer patients with BM and known HER2 and HR status.
Methods
Study population
Medical records of breast cancer patients with BM were
retrospectively extracted from the databases of two
French cancer centers. Patients were accrued over a 15-
year period, between 1995 and 2010. Inclusion criteria
were as follows: histologically proven breast carcinoma,
intradural BM detected by contrast-enhanced cerebral
computed tomography or magnetic resonance imaging,
and known HR and HER2 status. The tumor was consid-
ered HR positive when more than 10% of cells were la-
beled in immunohistochemistry (IHC) or when the
concentrations of estrogen and progesterone receptors
were above 10 ng/ml and 50 ng/ml using the radioligand
binding method, respectively. The tumor was considered
HER2 positive if the primary tumor was scored 3+ by
IHC or if the HER2 gene was amplified by fluorescence
in situ hybridization (FISH). If the tumor was scored 2+
by IHC, it was re-analyzed using FISH. Patients with his-
tory of other primitive carcinoma or leptomeningeal car-
cinomatosis were excluded. In addition, an additional
brain MRI was performed to all patient presenting with
1 to 3 BM at baseline CT-scan. Clinical data and, when
available, biological parameters were extracted in order
to score patients using the RPA [1], the GPA [2], the BS-
BM [3], the P1PS [4], the Breast-GPA [12], the Breast-
RPA [14] and Le Scodan’s score [13], whose constituting
parameters are detailed in Table 1. Ethical approval,
as well as permission to create, complete and access the
comprehensive database used in this study, was provided
by the local research ethics committee of the Val d’Aurelle
Cancer Institute. Due to the retrospective, non interven-
tional nature of this study, no consent was requested by
the local research ethics committee.
Statistical analyses
Categorical variables were reported by means of contin-
gency tables. For continuous variables, median and range
values were computed. To investigate the association be-
tween study features, univariate statistical analyses were
performed using Pearson’s Chi-2 test or Fisher’s exact
test if applicable for categorical variables. The Kruskal-
Wallis test or Student T test were used for continuous
Table 2 Study population
Patient characteristics Number of
patients
%
Age at breast cancer
diagnosis (years)
Median, range 50 (23–82)
Age at BM diagnosis (years)
Median, range 55 (25–85)
Time between initial diagnosis and BM
diagnosis (months)





















Anti-HER2 treatment for HER2+ patients
Yes 20 18.3
No 89 81.7
BM, Brain Metastases, KPS, Karnofsky Performance Status.
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the date of BM diagnosis to the date of death from any
cause. Patients alive without event were censored at the
closing date of the study analysis (August 1st, 2011). OS
rates and median values were estimated according to the
Kaplan-Meier method [15], and presented with their
95% confidence intervals (95% CIs). The median length
of follow-up was estimated using a reverse Kaplan-Meier
method and presented with 95% CIs.
Pair wise comparisons of subgroups were performed
for each score. Survival curves were drawn and the log-
rank test was performed to assess differences between
groups. Harrell’s concordance Index (C index) was used
to assess the discriminating ability of the different PIs
[16]. To investigate prognostics factors, multivariate
analyses were carried out using the Cox’s proportional
hazards regression model with a stepwise selection pro-
cedure [17,18]. Hazard ratios (HR) with 95% CIs are
presented to display risk reductions. All p values
reported are two-sided, and the significance level was
set at 5% (p < 0.05). Statistical analysis was performed




There were a total of two hundred and fifty patients
included in this analysis. Patient characteristics are
detailed in Table 2. At the time of BM diagnosis, the me-
dian age was 55 years (range 25–85), and 74% of patients
had good performance status (80–100). The brain was
the first metastatic site in about one third of patients
(34%), and the only site of metastatic disease in 12% of
patients. Of the 250 patients, 44% had a primary tumor
that over-expressed HER2, while 26% were diagnosed
with a triple negative breast cancer (negative HR and
HER2 status). A total of 47 patients (18.8%) underwent
targeted local treatment, namely stereotactic radiother-
apy or surgery. Whole brain radiation therapy (WBRT),
used as primary treatment but also as adjuvant treat-
ment after localized treatment, was given to 217 patients
(86.8%). Fifteen patients received best supportive care
only. After a median follow-up of 4.5 years, the median
OS (MOS) was 8.9 months (95% CI, 6.9-10.3 months).
The six-month, one-year and two-year overall survival
rates were 61% (95% CI, 54-67%), 40% (95% CI, 34-46%)
and 22% (95% CI, 17-27%), respectively.
Prognostic indexes analysis
Table 3 lists the study population distribution as well as
the MOS for each PI. Survival curves are depicted in
Figure 1. The results showed that all scores were able to
discriminate with statistical significance (p < 0.001)
patients for OS according to the prognostic category.MOS times for the RPA classes I, II and III were 25.6
months (95% CI 18.4-32.9), 10.4 months (95% CI 8.9-
12.6), and 2 months (95% CI 1.4-3.1), respectively. For
the GPA classes I, II and III, the MOS were 25.6 months
(95% CI 3.1-5.4), 12.3 months (95% CI 10.1-15.1), and
24.7 months (95% CI 12.7-27.1), respectively. In patients
stratified in the classes I, II, III and IV using the BS-BM
prognostic scores, the MOS were 2.2 months (95% CI
1.4-3.6), 8.7 months (95% CI 6.1-12.3), 12.7 months
(95% CI 12.7-27.1), and 21.6 months (95% CI 12.7-25.6),
respectively. With respect to the P1PS, ninety-one
patients could not be classified due to missing bio-
logical data. The MOS were 16.4 months (95% CI 11.9-
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patients with P1PS scores of 0/1 vs. 2/3, respectively.
Based on the breast GPA scoring system, MOS were
found to be 2.3 months for a score of 0–1 (95% CI 1–
4.1), 5.7 months for a score of 1.5-2.5 (95% CI 4–8),
10.3 months for a score of 3 (95% CI 8.4-13.7), and 18.4
months for a score > 3 (95% CI 12.4-23.3). The MOS
were 21.3 months (95% CI 9.7-53.9) for class I, 9.8
months (95% CI 8.4-12.1) for class II, and 2.3 months
(95% CI 1.8-4.3) for class III according to the breast
RPA scoring system. Lastly, the MOS for Le Scodan’
scores I, II and III were 15.2 (95% CI 11.5-19.4), 9.7
(95% CI 7.5-12.4), and 4.2 (95% CI 3.3-6.1) months,
respectively.Table 3 Distribution of the study population and median ove
Harrell’s concordance indexes (HCS)
Number of pts (%) MOS (95% CI)
RPA
1 26 (10.4) 25.6 M (18.4–32.9)
2 166 (66.4) 10.4 M (8.9–12.6)
3 58 (23.2) 2 M (1.4–3.1)
GPA
≥3 32 (12.8) 24.7 M (12.7–27.1)
1.5-2.5 116 (46.4) 12.3 M (10.1–15.1)
0-1 102 (40.8) 4.2 M (3.1–5.4)
BS-BM
3 31 (12.4) 21.6 M (12.7–25.8)
2 68 (27.2) 12.7 M (9.7–18.4)
1 96 (38.4) 8.7 M (6.1–12.3)
0 55 (22.0) 2.2 M (1.4–3.6)
P1PS
0–1 95 (38.0) 16.4 M (11.9–23.3)
2–3 64 (25.6) 5.9 M (3.4–8.4)
Not available 91 (36.4)
Breast GPA
3.5-4 53 (21.2) 18.4 M (12.4–23.3)
3 90 (36.0) 10.3 M (8.4–13.7)
1.5-2.5 76 (30.4) 5.7 M (4–8)
0-1 31 (12.4) 2.3 M (1–4.1)
Breast RPA
1 20 (8.0) 21.3 M (9.7–53.9)
2 192 (76.8) 9.8 M (8.4–12.1)
3 38 (15.2) 2.3 M (1.8–4.3)
Le Scodan Score
1 89 (35.6) 15.2 M (11.5–19.4)
2 49 (19.6) 9.7 M (7.5–12.4)
3 112 (44.8) 4.2 M (3.3–6.1)
CI, Confidence Interval. MOS, Median Overall Survival (from brain metastases diagnoPairwise comparisons of each PI revealed statistically
significant differences in survival between prognostic clas-
ses except for the breast GPA classes I vs. II (p = 0.0609),
the BS-BM scores 1 vs. 2 (p = 0.27), and Le Scodan’s scores
I vs. II (p = 0.098).
Prognostic indexes comparison
There were no statistically significant differences be-
tween all PIs with regard to survival predicting abi-
lity (Table 3). Only minor differences were seen using
Harrell’s concordance index, with values of Harrell’s C
slightly higher for the BS-BM (0.6803) and RPA (0.6783)
scoring systems than for the breast RPA (0.6037), Le
Scodan’s score (0.6239), and P1PS (0.6251). Inrall survival according to the class of prognostic scores;
p Hazard Ratio (95% CI) HCS (95% CI)
1 0.6783
<0.001 2.16 (1.34–3.50) (0.65–0.71)
11.38 (6.57–19.70)
1 0.658







<0.001 2.89 (2.01–4.14) (0.58–0.66)
1 0.6587




<0.001 2.05 (1.20–3.50) (0.57–0.63)
6.84 (3.69–12.72)
1 0.6239
<0.001 1.32 (0.91–1.92) (0.58–0.66)
1.92 (1.43–2.59)
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Figure 1 Overall survival according to (A) the RPA, (B) the BS-BM, (C) the GPA, (D) the Breast RPA, (E) the Breast GPA, (F) Le Scodan’s
score, (G) the P1PS score.
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Table 4 Multivariate Cox regression analyses (stepwise
procedure) on (a) general population and (b) population
with available biological parameters
a) HR 95% CI P
RPA 2 2.76 1.64–4.66 <0.001
RPA 3 8.42 4.36–16.26 <0.001
Le Scodan 2 1.49 1.01–2.19 0.041
Le Scodan 3 1.87 1.30–2.69 0.001
GPA 3 1.75 1.22–2.51 0.002
b) HR 95% CI P
RPA 2 2.42 1.36–4.29 0.003
RPA 3 13.26 6.94–25.30 <0.001
Le Scodan 3 1.57 1.03–2.39 0.035
P1PS 2/3 2.23 1.54–3.24 <0.001
RPA, recursive partitioning analysis, GPA, graded partitioning analysis, P1PS,
phase 1 prognostic score, HR, hazard ratio, CI, confidence interval.
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only available for 159 patients), the RPA, Le Scodan’s
score, and GPA were found to be the best independent
predictors of overall survival. In a second multivariate
analysis restricted to the 159 patients with known serum
LDH level and proteinemia, the RPA 2 and 3, Le Sco-
dan’s score 3 and P1PS 2/3 were associated with worse
survival (Table 4).
When evaluating the ability of the different scores to
correctly stratify patients with short or long life expect-
ancy, the patients with a MOS longer than 12 months
accounted for 85%, 75%, 71%, 70%, 68%, 58% and 58% of
the “good prognosis” population defined as RPA 1,
GPA ≥ 3, BS-BM 3, Breast RPA 1, Breast GPA 3.5-4, Le
Scodan 1, BS 0–1, respectively. Patients with a MOS
shorter than 3 months accounted for 62%, 39%, 60%,
58%, 61%, 37.5%, and 34% of the “poor prognosis”:
population defined as RPA 3, GPA 0–1, BS-BM 0, Breast
RPA 3, Breast GPA 0–1, Le Scodan 3, BS 2–3, respect-
ively. The misclassification rates in patients living more
than 12 months but classified as “poor prognosis” popu-
lation were 3%, 17%, 5.5%, 8%, 6.5%, 26% and 25%, re-
spectively. Conversely, the misclassification rates in
patients living less than 3 months but classified as “good
prognosis” population were 0%, 0%, 3%, 5%, 2%, 4.5%
and 7%, respectively.
Discussion
This comprehensive and simultaneous analysis of 7
prognostic scores was performed on a large, well-
characterized and homogeneous population of 250
breast cancer patients with BM. This study examined
three common scores, namely the RPA, the GPA, and
the BS-BM, as well as four new scores incorporating bio-
logical or breast-specific parameters: the breast RPA, the
breast GPA, Le Scodan’s score, and the P1PS. Withrespect to other scoring systems, the Rotterdam score
was not investigated since it uses, as a prognostic vari-
able, the clinical response to steroid therapy prior to
panencephalic radiotherapy, which is a subjective infor-
mation not necessarily collected in clinical observations
[5]. In the same way, neither the volume of the largest
BM, nor the time between BM diagnosis and the begin-
ning of radiotherapy were available to calculate the SIR
[6] and Rades [7] scores, respectively.
Until recently, there have been few studies focusing on
BM prognostic scores in breast cancer. Yet, it has been
demonstrated that the reliability and clinical relevance of
these scores vary greatly depending on the type of pri-
mary tumor. Sperduto et al. found that, in a population
of 4,259 patients with 642 breast cancers, the GPA was
unfit not only for breast tumor, but also for gastrointes-
tinal, melanoma, and renal cell cancer [8]. Similarly, the
widely used RPA index has some limitations in breast
disease as it does not consider specific tumor markers,
such as the status of HR and HER2. Moreover, the de-
scription of extra-cerebral disease is probably not the
best suited variable for this pathology, since the progno-
sis of women with bone metastases or locoregional
recurrences differs from that of patients with liver or
lung metastases. Recently, efforts have been made to im-
prove accuracy of previous classifications by taking into
account breast cancer biomarkers. As such, the GPA
score has been replaced by a score specific to breast can-
cer integrating the status of both HER2 and HR [12].
Likewise, Le Scodan’s score, including the breast cancer
molecular subtype and treatment parameters, has been
proposed from a retrospective analysis of a selected
population of patients presenting with advanced disease
[12].
Overall, our results indicated that the different scores
were able to discriminate the prognosis of patients,
which is in keeping with the analysis of Nieder et al.
who compared a variety of prognostic classifications
from all published trials performed on more than 20
patients [19]. However, the new classifications failed to
improve patient selection, with the Breast GPA and
Breast RPA scores showing lower Harrell’s concordance
indexes than the original RPA score. The diversity of
populations between studies might explain discrepancies
in results and makes generalization difficult. Indeed, the
patients analyzed in the Breast GPA pivotal study did
not reflect daily clinical practice since 62% of patients
presented 1 to 3 BM, 35% had BM without extra-cranial
metastases, 37% were aged less than 50 years, 57% had
tumors overexpressing HER2 receptor, and 68% of
patients received targeted local treatments, which prob-
ably explains an impressively good survival (13.8
months). Regarding the results from the Breast RPA piv-
otal study, in comparison of our study population, the
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tion bias related to the treatment received after BM
diagnosis compared to a general clinical practice situ-
ation [14]. Contrary to previous indexes, Le Scodan’s
score had an independent prognostic value in multipara-
metric analysis, emphasizing the importance of bio-
logical subtypes and blood parameters [13]. However,
the drawback is that the definition of biological subtype
varies depending on the author. Le Scodan et al. distin-
guished between HER2 positive population treated with
trastuzumab and triple negative breast cancer [13], while
Sperduto et al. [12] and Niwinska et al. [14] distin-
guished between luminal A, B, HER2, and basal tumors.
In these last two studies, 77% and 50% of the HER2+
population were treated using anti-HER2 agents, re-
spectively. It would have been interesting to integrate, as
did Le Scodan, the anti-HER2 treatment in the biological
subtype since there is increasing evidence that anti-
HER2 treatments prolong survival of breast cancer
patients with BM [9-11,20]. Biological parameters,
such as lymphopenia for Le Scodan’s score and LDH
and proteinemia for the P1PS [4], have been shown to
have an independent prognostic value on multiparametric
analysis and thus warrant further evaluation. Evaluating
subclinical disease activity and the impact on nutritional
status may confer additional prognostic information.
One of the strengths of our study is to reflect routine
clinical practice population, without selection based on
performance status, number of metastases or treatment.
This is essential to provide physicians with a clinical tool
applicable to the whole patient population at the time of
BM diagnosis. According to our analysis, the RPA score
can still be considered as the reference score for several
reasons. Firstly, although Harrell’s concordance Indexes
were quite similar for all PIs, the hazard ratio of the
RPA was higher than those of other PIs in multivariate
analysis. Our results were consistent with those reported
by (i) Le Scodan et al. [21] and Mahmoud-Ahmed et al.
[22] who confirmed the prognostic value of the RPA
score in the setting of BM from breast cancer (ii) Viani
et al. who found a superiority of the RPA score over the
BS-BM one [23]. Secondly, one must keep in mind the
primary goal of these classifications which is to adapt
treatment options to the individual patient prognosis.
We need to mitigate the treatment burden for patients
with short life expectancy, and conversely to intensify
therapeutic interventions for patients for whom an im-
provement in overall survival is expected. Hence, it is
important to know how often the prognostic scores
wrongly categorize patients in inappropriate prognosis
groups. Nieder et al. studied their ability to correctly
classify patients with good prognosis (MOS longer than
6 months from the diagnosis of BM) and patients with
poor prognosis (MOS shorter than 2 months from thediagnosis of BM) [24]. In our study, the MOS was 8.9
months and 40% of the population was alive at 1 year, so
we decided to adapt the cut offs used by Nieder to our
study population, and we considered boundaries to be a
MOS of less than 3 months and a MOS of more than 12
months. In these circumstances, the RPA proved to be
more efficient than the other scores to predict median sur-
vival since 85% of patients classified as RPA 1 survived
more than 12 months, and 62% of patients classified as
RPA 3 survived less than 3 months. Furthermore, the RPA
misclassified a smaller proportion of patients than the
other scoring systems as no patients classified RPA 1 sur-
vived less than 3 months and only 3% of patients classified
as RPA 3 survived more than 12 months.
A particular weakness of some of the classification sys-
tems is the lack of homogeneous distribution of patients
between the different prognostic categories. Indeed, a
score that would identify a subgroup with excellent
prognosis in a very small number of patients, a situation
rarely seen in clinical practice, would have limited im-
pact to aid therapeutic decision making in routine prac-
tice. This is one of the pitfalls of the GPA scoring since
the class 3.5-4 of better prognosis accounts only for
2.8% of our daily clinical practice population. Finally, an
ideal prognostic score should be simple and easily usable
in clinical practice. Our analysis at this stage differs from
that of Sperduto et al. [2] in so far that we believe that
the RPA score is more readily reproducible in practice
thanks to a limited number of variables to be collected
and fewer prognostic classes.
Nevertheless, due to its retrospective nature, our study
suffers some limitations. First, in retrospective analysis, it
could be difficult to assess controlled versus uncontrolled
distant metastases. As this information is required in
Breast RPA prognostic index, the retrospective analysis
of this factor could have misclassified some patients.
Similarly, a retrospective evaluation of KPS appears less
reliable than the evaluation of Performance Status using
ECOG classification, and could have led to some degrees
of misclassification.
Conclusion
The new PIs did not perform better than the original
scores. Although tumor subtypes, HER2 expression, and
blood parameters (LDH, proteinemia, lymphopenia) may
have an interesting additional prognostic value, the RPA
appears to be the most appropriate and simplest avail-
able tool to help clinicians select breast cancer patients
with BM.
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